Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Corrado Altomare

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Menopause (New York, N.Y.)|July 9, 2015
Ospemifene should be used as a single agent without progestin in postmenopausal women with an intact uterusCorrado Altomare
Menopause (New York, N.Y.)|May 17, 2017
Ospemifene's effects on lipids and coagulation factors: a post hoc analysis of phase 2 and 3 clinical trial dataDavid F Archer, Corrado Altomare, Wei Jiang, et al.
Journal of Women'S Health (2002)|October 25, 2017
Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 TrialsJames A Simon, Corrado Altomare, Susannah Cort, et al.
Menopause (New York, N.Y.)|July 13, 2016
Ospemifene's effect on vasomotor symptoms: a post hoc analysis of phase 2 and 3 clinical dataGinger D Constantine, David F Archer, Ricki Pollycove, et al.
Menopause (New York, N.Y.)|May 14, 2009
Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginallyGloria Bachmann, Céline Bouchard, Diana Hoppe, et al.
Menopause (New York, N.Y.)|August 28, 2019
Effects of ospemifene on genitourinary health assessed by prospective vulvar-vestibular photography and vaginal/vulvar health indicesIrwin Goldstein, James A Simon, Andrew M Kaunitz, et al.
Maturitas|November 7, 2020
No increase in incidence or risk of recurrence of breast cancer in ospemifene-treated patients with vulvovaginal atrophy (VVA)Bin Cai, James Simon, Paola Villa, et al.
Menopause (New York, N.Y.)|January 30, 2019
Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trialDavid F Archer, Steven R Goldstein, James A Simon, et al.
Journal of Women'S Health (2002)|May 15, 2015
The impact of multimorbidity on quality of life among midlife women: findings from a U.S. nationally representative surveyKathleen Lang, Ivy M Alexander, James Simon, et al.
Scientific Reports|July 27, 2025
Laser-driven proton sources for efficient radiation testingBeatrice D'Orsi, Corrado Altomare, Alessandro Ampollini, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Menopause (New York, N.Y.)|July 9, 2015
Ospemifene should be used as a single agent without progestin in postmenopausal women with an intact uterusCorrado Altomare
Menopause (New York, N.Y.)|May 17, 2017
Ospemifene's effects on lipids and coagulation factors: a post hoc analysis of phase 2 and 3 clinical trial dataDavid F Archer, Corrado Altomare, Wei Jiang, et al.
Journal of Women'S Health (2002)|October 25, 2017
Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 TrialsJames A Simon, Corrado Altomare, Susannah Cort, et al.
Menopause (New York, N.Y.)|July 13, 2016
Ospemifene's effect on vasomotor symptoms: a post hoc analysis of phase 2 and 3 clinical dataGinger D Constantine, David F Archer, Ricki Pollycove, et al.
Menopause (New York, N.Y.)|May 14, 2009
Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginallyGloria Bachmann, Céline Bouchard, Diana Hoppe, et al.
Menopause (New York, N.Y.)|August 28, 2019
Effects of ospemifene on genitourinary health assessed by prospective vulvar-vestibular photography and vaginal/vulvar health indicesIrwin Goldstein, James A Simon, Andrew M Kaunitz, et al.
Maturitas|November 7, 2020
No increase in incidence or risk of recurrence of breast cancer in ospemifene-treated patients with vulvovaginal atrophy (VVA)Bin Cai, James Simon, Paola Villa, et al.
Menopause (New York, N.Y.)|January 30, 2019
Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trialDavid F Archer, Steven R Goldstein, James A Simon, et al.
Journal of Women'S Health (2002)|May 15, 2015
The impact of multimorbidity on quality of life among midlife women: findings from a U.S. nationally representative surveyKathleen Lang, Ivy M Alexander, James Simon, et al.
Scientific Reports|July 27, 2025
Laser-driven proton sources for efficient radiation testingBeatrice D'Orsi, Corrado Altomare, Alessandro Ampollini, et al.
Pageof 1